









Markets
/
Stocks
/
nasdaq-rapt
/

RAPT Therapeutics Inc

RAPT

57.690USD

+0.010+0.02%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

972.39MMarket Cap

LossP/E TTM



RAPT Therapeutics Inc

57.690

+0.010+0.02%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of RAPT Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

RAPT Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 109 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 53.89.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

RAPT Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

109 / 392

Overall Ranking

239 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

RAPT Therapeutics Inc Highlights

StrengthsRisks

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -4.96, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 18.74M shares, increasing 0.60% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.19M shares of this stock.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

53.889

Target Price

-6.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of RAPT Therapeutics Inc is 5.74, ranking 331 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.74

Change



Financials

2.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

RAPT Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of RAPT Therapeutics Inc is 6.76, ranking 227 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.96, which is -99.41% below the recent high of -0.03 and -141.11% above the recent low of -11.95.

Score

Industry at a Glance

Previous score

6.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 109/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of RAPT Therapeutics Inc is 6.36, ranking 336 out of 392 in the Biotechnology & Medical Research industry. The average price target is 60.00, with a high of 72.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

6.36

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

53.889

Target Price

-6.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

RAPT Therapeutics Inc

RAPT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of RAPT Therapeutics Inc is 9.83, ranking 1 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 66.37 and the support level at 40.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.86

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.032

Neutral

RSI(14)

79.696

Buy

STOCH(KDJ)(9,3,3)

48.366

Sell

ATR(14)

1.721

Low Volatility

CCI(14)

73.258

Neutral

Williams %R

42.500

Buy

TRIX(12,20)

2.431

Sell

StochRSI(14)

2.728

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

57.716

Sell

MA10

57.677

Buy

MA20

50.566

Buy

MA50

40.456

Buy

MA100

33.992

Buy

MA200

21.765

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of RAPT Therapeutics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 64.73%, representing a quarter-over-quarter increase of 5.05%. The largest institutional shareholder is The Vanguard, holding a total of 1.19M shares, representing 4.10% of shares outstanding, with 34.52% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Medicxi Ventures (UK) LLP

2.79M

Forbion Capital Partners

1.83M

+432.58%

TCG Crossover Management, LLC

1.64M

Foresite Capital Management, LLC

1.56M

RTW Investments L.P.

1.47M

The Vanguard Group, Inc.

Star Investors

696.19K

-20.89%

OrbiMed Advisors, LLC

1.09M

-33.82%

Boone Capital Management LLC

782.46K

Deep Track Capital LP

751.42K

Nantahala Capital Management, LLC

623.28K

-34.50%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of RAPT Therapeutics Inc is 3.44, ranking 143 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.